HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Philippé, J. Articles by Baele, G. Search for Related Content PubMed PubMed Citation Articles by Philippé, J. Articles by Baele, G. Related Collections Hemostasis and Thrombosis

Comparison of Five Different Citrated Tubes and Their in Vitro Effects on Platelet Activation

¹ Department of Clinical Chemistry, Microbiology and Immunology, University Hospital Ghent, De Pintelaan 185, B-9000 Ghent, Belgium

^aauthor for correspondence: fax 32-9-2404985, e-mail jan.philippe@ugent.be

The first 20% of the full text of this article appears below.

After blood is collected in a tube, platelet activation occurs rapidly, hampering studies of other causes of platelet activation (1)(2)(3). Ideally, collection tubes for such studies have minimal activation potential. In vitro platelet activation has consequences for the evaluation of heparin activity as well (4) because activated platelets might release platelet factor 4 (PF4), inactivating heparin and leading to artifactual shortening of activated partial thromboplastin time (APTT) results.

To evaluate platelet activation, markers appearing on the cell surface can be studied, as can the release of products from platelet -granules. The purpose of this study was to evaluate the effect of blood sampling tubes on platelet activation. We compared five tubes:

• VT-050SBCS07 [Terumo Venoject® glass, containing 0.5 mL of buffered sodium citrate solution (32 g/L; final concentration, 0.109 mol/L), hereafter called tube 1;
  
• VF-054SBCS07 [Terumo Venosafe^TM plastic, containing 0.4 mL of buffered sodium citrate solution (32 g/L; final concentration, 0.109 mol/L), hereafter called tube 2;
  
• VF-053SBCS07 [Terumo Venosafe plastic, containing 0.3 mL of buffered sodium citrate solution (32 g/L; final concentration, 0.109 mol/L)], hereafter called tube 3;
  
• BD363079 [BD Vacutainer^TM Plus, containing 0.3 mL of sodium citrate solution (final concentration, 0.129 mol/L) in a plastic coagulation tube]; hereafter called tube 4; and
  
• GR454332 [Greiner Vacuette® Coagulation plastic tube, containing 0.35 mL of sodium citrate solution (32 g/L; final concentration, 0.109 mol/L)]; hereafter called tube 5.
  

Because there is a 9:1 blood:citrate volume ratio in the tubes, the final citrate concentration after tubes are filled with blood is 0.0109 mol/L in all tubes except for tube 4, which has a final concentration of 0.0129 mol/L.

We measured CD62, or P-selectin (GMP-140; PADGEM), which is a platelet -granule protein expressed . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				R. Zimmermann, J. Koenig, J. Zingsem, V. Weisbach, E. Strasser, J. Ringwald, and R. Eckstein Effect of Specimen Anticoagulation on the Measurement of Circulating Platelet-Derived Growth Factors Clin. Chem., December 1, 2005; 51(12): 2365 - 2368. [Full Text] [PDF]